Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDP-124 (Pimecrolimus) in Moderate to Severe Atopic Dermatitis
NCT03002571Phase 3Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Jul 2018
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Pimecrolimus vehicle + topical corticosteroid in atopic dermatitis (AD), sponsored by Valeant Pharmaceuticals. Started Jul 2018; status: completed.
02
Drugs
Pimecrolimus vehicle + topical corticosteroid
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT03002571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03002571.